Dr Reddy's Laboratories (Dr Reddy's Laboratories) Net Cash per Share : $-2.35 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Dr Reddy's Laboratories's Net Cash per Share for the quarter that ended in Dec. 2023 was $-2.35.

The historical rank and industry rank for Dr Reddy's Laboratories's Net Cash per Share or its related term are showing as below:

RDY's Price-to-Net-Cash is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.47
* Ranked among companies with meaningful Price-to-Net-Cash only.

Dr Reddy's Laboratories Net Cash per Share Historical Data

The historical data trend for Dr Reddy's Laboratories's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Net Cash per Share Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Cash per Share

Get a 7-Day Free Trial

-5.25

-4.17

-4.79

-4.58

-2.13

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															-2.96	-2.13	-2.25	-1.89	-2.35

Competitive Comparison of Dr Reddy's Laboratories's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Price-to-Net-Cash falls into.

Dr Reddy's Laboratories Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Dr Reddy's Laboratories's Net Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as

	Net Cash per Share (A: Mar. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(751.181	-	1104.496	-	0)	/	166.157
=	-2.13

Dr Reddy's Laboratories's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(869.111	-	1261.105	-	0)	/	166.513
=	-2.35

Dr Reddy's Laboratories (NYSE:RDY) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Dr Reddy's Laboratories Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Net Cash per Share

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.